2023-05-12 09:09:37 ET
- Protagonist Therapeutics ( NASDAQ: PTGX ) shared data from its partnership with Janssen Biotech, regarding the development of JNJ-2113.
- The pre-clinical data presented by Protagonist and Janssen Biotech on JNJ-2113 showed promising results in disease models for skin inflammation and colitis, indicating the potential for JNJ-2113 to be a first-in-class oral therapy targeting IL-23-mediated diseases like psoriasis and inflammatory bowel diseases.
- Janssen and Protagonis co-authored the report, which presented findings from Phase 1 and preclinical studies of JNJ-2113, a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity.
- The data showed potent, selective inhibition of IL-23 signaling in human T cells and systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis.
- JNJ-2113 demonstrated efficacy in a rat trinitrobenzene sulfonic acid (TNBS)-induced colitis model, and in an IL-23-induced rat skin inflammation model.
- Oral treatment with JNJ-2113 provided selective systemic IL-23 pathway inhibition in preclinical models that translated to systemic pharmacodynamics activity in healthy human volunteers, indicating potential for JNJ-2113 as a first-in-class oral therapy targeting IL-23-mediated diseases .
For further details see:
Protagonist Therapeutics and Janssen's collaboration shows promise for oral therapy for IL-23-mediated diseases